NIH | National Cancer Institute | NCI Wiki  

Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Excerpt

Cancer patients and their doctors choose from a range of different treatment options. But often the chosen treatment is ineffective, reducing quality and length of life and increasing cost.   Today  Today treatment decisions and outcomes occur in isolation. All4Cure has built a patient-centered, web-based, knowledge sharing platform that graphically portrays treatments and responses extracted from the medical records of de-identified patients with multiple myeloma (the second most common form of blood cancer) for comment by a community of participating patients, clinicians and researchers. Having assembled more than 580 participants we will describe examples of patients have benefited from their participation.

 

Session details...

 

...

Dr. Tony Blau founded All4Cure after 27 years as a Professor of Medicine/Hematology and physician-scientist at the University of Washington (UW). His research has spanned hematopoiesis, gene therapy, stem cell biology, genomics and cancer, consistently focusing on bringing the very latest research advances to patients with heretofore incurable diseases. At UW he UW Dr. Blau founded the Center for Cancer Innovation, which brings together a distributed network of investigators to help patients with advanced cancer. Dr. Tony Blau co-founded the UW Institute for Stem Cell and Regenerative Medicine and chaired the Molecular and Cellular Hematology Study Section for the National Institutes of Health. He has authored more than 90 scientific publications. Diagnosed himself with myeloma in April 2015, Tony  Dr. Blau infuses All4Cure with an incredible sense of urgency to improve the prospects for cancer patients now and in the future.

...

Topic:  A Cancer Patient's War on Cancer 

Speaker:  C. Anthony Blau, M.D., Professor of Hematology  at the Hematology, University of Washington School of Medicine in Seattle

Date: Wednesday, September 12, 2018

...